Celldex sinks as safety concerns cloud immune drug results

Data ReadoutMixedbarzolvolimabNegative

AI Analysis

Summary

Celldex's barzolvolimab showed the best efficacy results to date for chronic skin hives, but the drug was associated with two life-threatening anaphylaxis cases, raising safety concerns and pressuring the stock downward.

Clinical Trial Data

Outcome Details

Best efficacy results to date against chronic skin hives, but associated with two life-threatening anaphylaxis cases

Importance:6/10

Sentiment:

-0.65

safety concernsanaphylaxisefficacyimmune drugclinical trial

Related Companies

$CLDX

Read the original article

Published by BioPharma Dive on September 22, 2026 3:42 PM

Read Original